Q2 2025 Performance Highlights - Order intake increased by 6% year-on-year, and the order book increased by 7% year-on-year[11] - Sales grew by 1%, driven by growth in Personal Health, but partially offset by performance in Diagnosis & Treatment and Connected Care[11] - Adjusted EBITA margin increased by 130 bps to 12.4%[11] - Free cash flow increased from slightly positive to EUR 0.2 billion-0.4 billion, net of Respironics settlement[11] Order Book and Regional Performance - The order book is up 7% year-on-year, with an improved margin profile driven by recently launched innovations[16] - The order book accounts for approximately 40% of revenue[16] Financial Performance by Segment - Diagnosis & Treatment sales decreased by 1%[26] - Connected Care sales decreased by 1%[30] - Personal Health sales grew by 6%[38] Productivity and Outlook - Productivity initiatives delivered EUR 344 million year-to-date and are on track to deliver EUR 800 million in 2025[46] - The adjusted EBITA margin range is increased by 50 bps to 11.3%-11.8%[11]

Core Insights - Royal Philips has announced the CE-marking of its SmartCT image reconstruction solution, enhancing decision-making in stroke and neurovascular treatment [1][3] - SmartCT is designed for the Philips Azurion neuro biplane system, providing real-time 3D imaging directly in the Angio suite, which accelerates treatment and improves clarity [2][9] - The technology is already in use at leading stroke centers globally, streamlining workflows and supporting timely interventions, particularly in mechanical thrombectomy procedures [3][4] Product Features - SmartCT 3.0 delivers cone-beam CT imaging in as little as 8 seconds, optimizing image quality for cerebral soft tissue and aiding in the visualization of vessel occlusions [9] - The system includes motion-compensated imaging for restless patients and features like SmartCT Dual Viewer for real-time image fusion and enhanced procedural planning [9] - Philips will showcase SmartCT 3.0 at LINNC Paris 2025, highlighting its capabilities for neuro-endovascular treatments [6] Company Overview - Royal Philips is a leading health technology company focused on improving health and well-being through innovation, with 2024 sales of EUR 18 billion and operations in over 100 countries [10][11] - The company specializes in diagnostic imaging, ultrasound, image-guided therapy, and personal health solutions, employing approximately 67,200 people [11]